search
Back to results

Device for Breathing Frequency Monitoring in Muscular Dystrophy

Primary Purpose

Muscular Dystrophies

Status
Completed
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
RespirHó
Sponsored by
IRCCS Eugenio Medea
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Muscular Dystrophies

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria:

  • documented DMD or LGMD2
  • loss of independent ambulation (wheelchair-bound patients)
  • ability to understand and follow test instructions and to report pain and discomfort.

Exclusion criteria:

  • presence of metal implants and cardiac pacemakers
  • relevant concomitant comorbidities (e.g.epilepsy)
  • behaviour and/or psychiatric disorders (e.g. emotional problems, anxiety, panic attacks).

Sites / Locations

  • IRCCS Medea

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Breathing frequency monitoring

Arm Description

Outcomes

Primary Outcome Measures

Safety of the device
Recording of any adverse events
Usability of the device (System Usability Scale)
System Usability Scale (SUS acceptance and wearability of the device):the scores range from 0 to 100 in 2.5-point increments, with higher values meaning high perceived usability of the system
Acceptability of the device (Technological Acceptance Measure)
Technological Acceptance Measure (TAM) questionnaire appropriate for the medical device: with higher values meaning high acceptance of the system

Secondary Outcome Measures

Accuracy in measuring the breathing frequency
Comparison between the measures of respiratory rate by using the device and by using already validated instrumentation: Optoelectronic Plethysmography (OEP), optoelectronic movement analysis system. Chest wall movements during breathing are simultaneously recorded by the RespirHó device and by Optoelectronic Plethysmography (OEP), in static conditions, and in particular, in supine and seated positions. OEP allows assessment of ventilatory and breathing pattern by measuring chest-wall movements related to breathing, by using motion capture principles. Using OEP as reference method it is possible to compare the data recorded with the thoracic and abdominal units of the device RespirHó with those obtained by using OEP for the thoracic and abdominal compartments

Full Information

First Posted
February 26, 2020
Last Updated
March 17, 2020
Sponsor
IRCCS Eugenio Medea
search

1. Study Identification

Unique Protocol Identification Number
NCT04313595
Brief Title
Device for Breathing Frequency Monitoring in Muscular Dystrophy
Official Title
A Wearable Device for Breathing Frequency Monitoring: a Pilot Study on Patients With Muscular Dystrophy
Study Type
Interventional

2. Study Status

Record Verification Date
March 2020
Overall Recruitment Status
Completed
Study Start Date
July 29, 2018 (Actual)
Primary Completion Date
July 15, 2019 (Actual)
Study Completion Date
July 15, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
IRCCS Eugenio Medea

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Patients at risk of developing respiratory dysfunctions, such as patients with severe forms of muscular dystrophy, need a careful respiratory assessment, and periodic follow-up visits to monitor the progression of the disease. Continuous monitoring of respiratory activity pattern at home could give additional understandings about disease progression, flanking traditional, intermittent, cardiopulmonary evaluations, allowing prompt clinical intervention, and anticipating respiratory dysfunction. The main objective of the present study is thus to investigate the feasibility of using an innovative wearable device for respiratory monitoring, especially breathing frequency variation assessment, in patients with muscular dystrophy. The comparison between the measurements of breathing frequency obtained by using the IMU-based device and by using the reference method provided optimal results, in terms of accuracy errors, correlation and agreement. Participants positively evaluated the device for what concerns ease of use, comfort, usability and wearability. Moreover, preliminary results confirmed that breathing frequency is an interesting breathing parameter to monitor, at the clinic and at home, because it strongly correlates with the main indexes of respiratory function

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Muscular Dystrophies

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
15 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Breathing frequency monitoring
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
RespirHó
Intervention Description
The system is a wearable, unobtrusive inertial-sensor-based device for long-term breathing pattern monitoring, also during daily life activities. It consists of three IMU-sensor units (3-axis accelerometer, 3-axis gyroscope, 3-axis magnetometer), positioned respectively on the patient's abdomen and thorax, and on a body area integral with thorax but not affected by espiratory movements. The peripheral units, placed on thorax and abdomen are used to record orientation changes during respiratory movements. The third unit is a central reference unit (hereafter CRU) that receives data from the other two units, save them on an SD card and communicate via Bluetooth with a smartphone / tablet / PC. Moreover, this unit detects only non-respiratory movement, representing not only a pure source of "noise" that must be removed from the thoracic and bdominal signals, but also a pure source of additional information regarding the state of ctivity of the subject .
Primary Outcome Measure Information:
Title
Safety of the device
Description
Recording of any adverse events
Time Frame
After 24 hours of continued use
Title
Usability of the device (System Usability Scale)
Description
System Usability Scale (SUS acceptance and wearability of the device):the scores range from 0 to 100 in 2.5-point increments, with higher values meaning high perceived usability of the system
Time Frame
After 24 hours of continued use
Title
Acceptability of the device (Technological Acceptance Measure)
Description
Technological Acceptance Measure (TAM) questionnaire appropriate for the medical device: with higher values meaning high acceptance of the system
Time Frame
After 24 hours of continued use
Secondary Outcome Measure Information:
Title
Accuracy in measuring the breathing frequency
Description
Comparison between the measures of respiratory rate by using the device and by using already validated instrumentation: Optoelectronic Plethysmography (OEP), optoelectronic movement analysis system. Chest wall movements during breathing are simultaneously recorded by the RespirHó device and by Optoelectronic Plethysmography (OEP), in static conditions, and in particular, in supine and seated positions. OEP allows assessment of ventilatory and breathing pattern by measuring chest-wall movements related to breathing, by using motion capture principles. Using OEP as reference method it is possible to compare the data recorded with the thoracic and abdominal units of the device RespirHó with those obtained by using OEP for the thoracic and abdominal compartments
Time Frame
Immediately after application of the device

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: documented DMD or LGMD2 loss of independent ambulation (wheelchair-bound patients) ability to understand and follow test instructions and to report pain and discomfort. Exclusion criteria: presence of metal implants and cardiac pacemakers relevant concomitant comorbidities (e.g.epilepsy) behaviour and/or psychiatric disorders (e.g. emotional problems, anxiety, panic attacks).
Facility Information:
Facility Name
IRCCS Medea
City
Bosisio Parini
State/Province
Lecco
ZIP/Postal Code
23842
Country
Italy

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Device for Breathing Frequency Monitoring in Muscular Dystrophy

We'll reach out to this number within 24 hrs